CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,257 enrolled
Drug / intervention
Dapagliflozin 10 MGdrug
Likely dose
Dapagliflozin 10 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04696185
NCT04696185Phase 4Completed
CompareCT.gov

Dapagliflozin After Transcatheter Aortic Valve Implantation

Spanish Society of Cardiology·interventional·Posted Jan 6, 2021·Updated Jan 10, 2025

In Brief

A Phase 4 clinical trial evaluating Dapagliflozin 10 MG for Aortic Stenosis and Transcatether Aortic Valve Implantation. Completed, enrolled 1,257 participants across 40 sites.

Detailed Summary

Pragmatic, controlled, prospective, randomized, open-label (open-label), evaluator-blind clinical trial (PROBE design) that will analyze the benefits of dapagliflozin treatment in patients with severe aortic stenosis discharged after implantation of an aortic valve prosthesis transcatheter (TAVI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis, Transcatether Aortic Valve Implantation
CountriesSpain
CollaboratorsFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJan 6, 2021
Enrollment StartJan 27, 2021
Primary CompletionDec 29, 2024
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.5 years ago

Interventions

Dapagliflozin 10 MGdrug

Dapagliflozin 10 mg (daily oral dose)